Researchers from Boston University have discovered that the drug ABT-263, which targets and eliminates senescent cells, has the potential to accelerate the healing of skin damage in older organisms. This research has been published in the journal Aging.
As organisms age, senescent cells, often referred to as “zombie cells,” accumulate in tissues. These cells, while no longer functional, continue to release signaling molecules that promote inflammation and impede tissue repair. It is believed that these cells are partly responsible for skin aging and the delayed healing of wounds.
The scientists set out to investigate whether the senolytic drug ABT-263 could effectively remove these senescent cells. Unlike conventional medications, senolytics are designed to selectively destroy aging cells. In their experiment, the researchers applied the drug to the skin of elderly mice for five days. Subsequently, small wounds were inflicted on the animals, and their healing rates were monitored.
The results indicated that the treatment reduced the markers of cellular aging and expedited tissue regeneration. By the 24th day, wounds had completely healed in 80% of the mice that received the drug, compared to only 56% in the control group.
An unexpected finding was that ABT-263 temporarily intensified inflammation. While inflammatory processes are typically considered detrimental, in this instance, the short-lived surge likely aided in “rebooting” regenerative mechanisms. In the treated animals, genes associated with collagen synthesis, blood vessel formation, and tissue remodeling were activated.
The authors highlight that aging skin not only thins and develops wrinkles but also exhibits a diminished capacity to respond to damage. This increases the likelihood of complications following surgical procedures and the development of chronic wounds in elderly individuals.
The topical application of the drug is of particular interest. When taken orally, senolytics can cause systemic side effects due to their widespread distribution throughout the body. Applying the drug directly to the skin allows for targeted action. Notably, the effect was negligible in younger mice, indicating that the drug specifically targeted areas where senescent cells had accumulated.
The researchers believe that in the future, such treatments could be employed prior to surgeries or for patients at risk of poor wound healing. However, this study was conducted solely on mice, and the efficacy of this method in humans remains to be determined.
About the Author
